Vaxil Bio

Vaxil Bio Enterprise Value

The Enterprise Value (EV) of Vaxil Bio (VXL.V) as of Oct 19, 2026 is 1.78 M CAD. In the previous year, Enterprise Value (EV) was 1.78 M CAD — a change of 0.00% (lower).

Enterprise Value

1.78 MCAD

YoY

0.00%

Last updated:

Enterprise Value (EV) of Vaxil Bio is 2025 1.78 M CAD. Enterprise Value (EV) of Vaxil Bio was 2024 1.78 M CAD. It decreases by 0.00% lower compared to the previous year.

The Vaxil Bio Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
1.03 M CAD
Jan 1, 2019
1.71 M CAD
Jan 1, 2020
279,727.00 CAD
Jan 1, 2021
-460,273.00 CAD
Jan 1, 2022
270,727.00 CAD
Jan 1, 2023
842,727.00 CAD
Jan 1, 2024
1.78 M CAD
Jan 1, 2025
1.78 M CAD
The Vaxil Bio Enterprise Value history
YEAREnterprise ValueYoY
1.78 MCAD0.00%
1.78 MCAD+111.31%
842,727.00CAD+211.28%
270,727.00CAD-158.82%
-460,273.00CAD-264.54%
279,727.00CAD-83.69%
1.71 MCAD+66.04%
1.03 MCAD-38.88%
1.69 MCAD+118.11%
774,727.00CAD-56.20%
1.77 MCAD+5.99%
1.67 MCAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vaxil Bio Stock analysis

What does Vaxil Bio do? Vaxil Bio Ltd is a biotechnology company based in Toronto, Canada, specializing in immunotherapy for cancer and infectious diseases. Listed on March 2, 2011, the firm develops novel treatments using a platform based on signal peptides. Its advanced product, ImMucin, is a vaccine derived from MUC1 signal peptides that completed Phase I/II trials for multiple myeloma. The company also holds candidates for COVID-19 and tuberculosis vaccines, as well as monoclonal antibodies for oncology and infectious diseases. Additionally, Vaxil Bio has initiated a pre-clinical program for a drug delivery polymer targeting E-selectin, licensed from BGN Technologies, aiming to create targeted therapies against critical disease targets. Vaxil Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vaxil Bio stock

Enterprise Value (EV) of Vaxil Bio is 1.78 M CAD in 2025.

Enterprise Value (EV) of Vaxil Bio changed from 1.78 M CAD to 1.78 M CAD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Vaxil Bio since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s CAD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' CAD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Vaxil Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Vaxil Bio

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Vaxil Bio